Seeking Alpha

Acadia Pharmaceuticals (ACAD +13.2%) pushes to a new 52-week high today on the back of a Seeking...

Acadia Pharmaceuticals (ACAD +13.2%) pushes to a new 52-week high today on the back of a Seeking Alpha article touting the potential of it's experimental anti-psychotic drug pimavanserin. On September 5, ACAD announced the completion of patient enrollment in a phase III study of the drug for treating Parkinson's disease psychosis. If approved, it will be the first antipsychotic drug to receive such approval, and will likely be immediately embraced, and extensively prescribed.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)